Daehan Nupharm Co.,Ltd.

Research Daehan Nupharm Co.,Ltd. (054670.KQ) on Bullrun: market cap KRW 74.53B, dividend yield 1.9%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is KRW 74.53B; dividend yield is 1.9%.

Peer valuation comparison

Latest dividend yield is 1.88% versus a Healthcare sector median of 2.4% (21.7% below).

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18KRW 74.53Bn/a1.9%100

Dividend history

Latest trailing dividend snapshot: annual dividend/share 100 KRW, yield 1.9%.

About Daehan Nupharm Co.,Ltd.

Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormones, dermatologic, central nervous system, anticonvulsive, amino acid, anesthetic, antiobesity, and others; vitamins;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Daehan Nupharm Co.,Ltd.'s market cap?

Daehan Nupharm Co.,Ltd.'s market capitalization is KRW 74.53B.

Does Daehan Nupharm Co.,Ltd. pay a dividend?

Daehan Nupharm Co.,Ltd. has a dividend yield of 1.9%.

What does Daehan Nupharm Co.,Ltd. do?

Daehan Nupharm Co.,Ltd. manufactures and sells pharmaceuticals and veterinary products in South Korea and internationally. It offers pharmaceuticals drugs for cardiovascular, endocrine system, neuropsychiatric, gastrointestinal, respiratory system, antipyretic, analgesic, anti-inflammatory, anti-infective, musculoskeletal, osteoporosis, anti-cancer, urogenital system, antifungal, antiviral, hormones, dermatologic, central nervous system, anticonvulsive, amino acid, anesthetic, antiobesity, and others; vitamins; and inorganic products.